With last year's FDA-approval of #lecanemab, the first drug to slow the progression of #Alzheimers, the field of dementia research has never been more promising. Dr. Jason Karlawish, co-director of the Penn Memory Center, explains other new technologies being developed at Penn Medicine that are contributing to the "biomarker revolution". #dementia #dementiaresearch